feedback welcome

Trazodone-agomelatine

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[draft revision][draft revision]
Line 6: Line 6:
* '''Day 1:''' reduce dosage of trazodone to 75-100 mg/day.
* '''Day 1:''' reduce dosage of trazodone to 75-100 mg/day.
* '''Day 8:''' stop administration of trazodone.
* '''Day 8:''' stop administration of trazodone.
-
| start =  
+
| start = {{StartAgomelatine}}
-
* '''Day 1:''' simultaneously start administration of agomelatine in a dosage of 25 mg/day.
+
-
* '''Day 8:''' only continue administration of agomelatine. If necessary, increase dosage of agomelatine to 50 mg/day.
+
| info =  
| info =  
* The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given.   
* The content of trazodone in the tablet, for example 100 mg or 150 mg, determines which exact doses are given.   
-
<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
 
}}
}}

Revision as of 12:54, 5 March 2010

Trazodone
Type Antidepressant
Group other
links
Medscape Trazodone
PubChem 5533
PubMed Trazodone
Kompas (Dutch) Trazodone
Wikipedia Trazodone
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from trazodone to agomelatine.

Nietinrijdenbord.png Stop trazodone
Eenrichtingbord.png Start agomelatine
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About